Trxade Group (MEDS)
(Delayed Data from NSDQ)
$5.92 USD
+0.16 (2.79%)
Updated May 13, 2024 03:54 PM ET
After-Market: $5.75 -0.17 (-2.87%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for TRxADE HEALTH, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 8 | 11 | 10 | 17 | 7 |
Cost Of Goods | 6 | 6 | 5 | 11 | 3 |
Gross Profit | 3 | 5 | 5 | 6 | 5 |
Selling & Adminstrative & Depr. & Amort Expenses | 10 | 10 | 10 | 8 | 5 |
Income After Depreciation & Amortization | -7 | -4 | -5 | -3 | 0 |
Non-Operating Income | -5 | 1 | 0 | 0 | 0 |
Interest Expense | 1 | 0 | 0 | 0 | 0 |
Pretax Income | -14 | -4 | -5 | -3 | 0 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -14 | -4 | -5 | -3 | 0 |
Extras & Discontinued Operations | -4 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -18 | -3 | -5 | -3 | 0 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -6 | -4 | -5 | -2 | 0 |
Depreciation & Amortization (Cash Flow) | 1 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -7 | -4 | -5 | -3 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.38 | 0.57 | 0.54 | NA | 0.40 |
Diluted EPS Before Non-Recurring Items | -3.61 | -6.15 | -7.50 | NA | 0.45 |
Diluted Net EPS (GAAP) | -7.49 | -6.15 | -9.75 | -4.95 | -0.75 |
Fiscal Year end for TRxADE HEALTH, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 1.72 | 2.06 | 2.25 | 2.25 |
Cost Of Goods | NA | 4.02 | 0.35 | 0.61 | 0.69 |
Gross Profit | NA | -2.31 | 1.70 | 1.64 | 1.56 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.42 | 2.55 | 1.99 | 1.90 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -5.73 | -0.85 | -0.35 | -0.34 |
Non-Operating Income | NA | 0.31 | 0.93 | -1.45 | 0.08 |
Interest Expense | NA | 0.70 | 0.25 | 0.18 | 0.06 |
Pretax Income | NA | -11.25 | -0.17 | -1.97 | -0.33 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -11.25 | -0.17 | -1.97 | -0.33 |
Extras & Discontinued Operations | NA | -0.42 | -3.35 | 0.00 | -0.35 |
Net Income (GAAP) | NA | -11.67 | -3.53 | -1.97 | -0.68 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 2.36 | 0.68 | 0.67 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.07 | -0.77 | -0.45 |
Diluted Net EPS (GAAP) | NA | -2.05 | -1.49 | -2.90 | -1.05 |